LIPOCINE INC (LPCN) Stock Fundamental Analysis

NASDAQ:LPCN • US53630X2036

8.66 USD
-0.01 (-0.12%)
At close: Feb 13, 2026
8.49 USD
-0.17 (-1.96%)
After Hours: 2/13/2026, 8:22:04 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to LPCN. LPCN was compared to 191 industry peers in the Pharmaceuticals industry. LPCN has a great financial health rating, but its profitability evaluates not so good. LPCN is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year LPCN was profitable.
  • LPCN had a negative operating cash flow in the past year.
  • LPCN had negative earnings in 4 of the past 5 years.
  • In the past 5 years LPCN always reported negative operating cash flow.
LPCN Yearly Net Income VS EBIT VS OCF VS FCFLPCN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M

1.2 Ratios

  • With a Return On Assets value of -34.06%, LPCN perfoms like the industry average, outperforming 47.12% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -38.72%, LPCN is in line with its industry, outperforming 58.12% of the companies in the same industry.
Industry RankSector Rank
ROA -34.06%
ROE -38.72%
ROIC N/A
ROA(3y)-33.24%
ROA(5y)-36.72%
ROE(3y)-36.81%
ROE(5y)-49.69%
ROIC(3y)N/A
ROIC(5y)N/A
LPCN Yearly ROA, ROE, ROICLPCN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

  • LPCN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LPCN Yearly Profit, Operating, Gross MarginsLPCN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • LPCN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for LPCN has been increased compared to 1 year ago.
  • The number of shares outstanding for LPCN has been increased compared to 5 years ago.
  • There is no outstanding debt for LPCN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LPCN Yearly Shares OutstandingLPCN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
LPCN Yearly Total Debt VS Total AssetsLPCN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -3.08, we must say that LPCN is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -3.08, LPCN is in line with its industry, outperforming 41.36% of the companies in the same industry.
  • There is no outstanding debt for LPCN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.08
ROIC/WACCN/A
WACC9.25%
LPCN Yearly LT Debt VS Equity VS FCFLPCN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

  • A Current Ratio of 8.25 indicates that LPCN has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 8.25, LPCN is in the better half of the industry, outperforming 74.35% of the companies in the same industry.
  • A Quick Ratio of 8.25 indicates that LPCN has no problem at all paying its short term obligations.
  • The Quick ratio of LPCN (8.25) is better than 74.87% of its industry peers.
Industry RankSector Rank
Current Ratio 8.25
Quick Ratio 8.25
LPCN Yearly Current Assets VS Current LiabilitesLPCN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 168.92% over the past year.
  • Measured over the past years, LPCN shows a very strong growth in Earnings Per Share. The EPS has been growing by 21.91% on average per year.
  • The Revenue for LPCN has decreased by -45.44% in the past year. This is quite bad
  • Measured over the past years, LPCN shows a very strong growth in Revenue. The Revenue has been growing by 133.89% on average per year.
EPS 1Y (TTM)168.92%
EPS 3Y21.91%
EPS 5YN/A
EPS Q2Q%-43.9%
Revenue 1Y (TTM)-45.44%
Revenue growth 3Y-11.47%
Revenue growth 5Y133.89%
Sales Q2Q%N/A

3.2 Future

  • LPCN is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -39.17% yearly.
  • LPCN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.92% yearly.
EPS Next Y-230.15%
EPS Next 2Y-78.85%
EPS Next 3Y-39.17%
EPS Next 5YN/A
Revenue Next Year-90.97%
Revenue Next 2Y-75.39%
Revenue Next 3Y-52.73%
Revenue Next 5Y37.92%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
LPCN Yearly Revenue VS EstimatesLPCN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 20M 40M 60M 80M
LPCN Yearly EPS VS EstimatesLPCN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -5 -10 -15 -20

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 16.98, LPCN is valued correctly.
  • Compared to the rest of the industry, the Price/Earnings ratio of LPCN indicates a rather cheap valuation: LPCN is cheaper than 86.39% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of LPCN to the average of the S&P500 Index (26.68), we can say LPCN is valued slightly cheaper.
  • The Forward Price/Earnings Ratio is negative for LPCN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 16.98
Fwd PE N/A
LPCN Price Earnings VS Forward Price EarningsLPCN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LPCN Per share dataLPCN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • A cheap valuation may be justified as LPCN's earnings are expected to decrease with -39.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-78.85%
EPS Next 3Y-39.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • LPCN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LIPOCINE INC

NASDAQ:LPCN (2/13/2026, 8:22:04 PM)

After market: 8.49 -0.17 (-1.96%)

8.66

-0.01 (-0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-11
Inst Owners18.59%
Inst Owner Change-96.63%
Ins Owners2.84%
Ins Owner Change0%
Market Cap48.06M
Revenue(TTM)4.32M
Net Income(TTM)-5.48M
Analysts82.5
Price Target11.09 (28.06%)
Short Float %2.71%
Short Ratio1.08
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-3.8%
Min EPS beat(2)-7.12%
Max EPS beat(2)-0.49%
EPS beat(4)2
Avg EPS beat(4)137.56%
Min EPS beat(4)-7.12%
Max EPS beat(4)555.88%
EPS beat(8)6
Avg EPS beat(8)100.41%
EPS beat(12)7
Avg EPS beat(12)53.04%
EPS beat(16)10
Avg EPS beat(16)134.32%
Revenue beat(2)1
Avg Revenue beat(2)57.05%
Min Revenue beat(2)-52.63%
Max Revenue beat(2)166.72%
Revenue beat(4)2
Avg Revenue beat(4)17.73%
Min Revenue beat(4)-74.1%
Max Revenue beat(4)166.72%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)58.18%
PT rev (3m)47.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.91%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-51.87%
Revenue NY rev (1m)-1.64%
Revenue NY rev (3m)-22.06%
Valuation
Industry RankSector Rank
PE 16.98
Fwd PE N/A
P/S 11.12
P/FCF N/A
P/OCF N/A
P/B 3.4
P/tB 3.4
EV/EBITDA N/A
EPS(TTM)0.51
EY5.89%
EPS(NY)-1.85
Fwd EYN/A
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.93
OCFYN/A
SpS0.78
BVpS2.55
TBVpS2.55
PEG (NY)N/A
PEG (5Y)N/A
Graham Number5.41
Profitability
Industry RankSector Rank
ROA -34.06%
ROE -38.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.24%
ROA(5y)-36.72%
ROE(3y)-36.81%
ROE(5y)-49.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.25
Quick Ratio 8.25
Altman-Z -3.08
F-Score2
WACC9.25%
ROIC/WACCN/A
Cap/Depr(3y)521.74%
Cap/Depr(5y)N/A
Cap/Sales(3y)9.09%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)168.92%
EPS 3Y21.91%
EPS 5YN/A
EPS Q2Q%-43.9%
EPS Next Y-230.15%
EPS Next 2Y-78.85%
EPS Next 3Y-39.17%
EPS Next 5YN/A
Revenue 1Y (TTM)-45.44%
Revenue growth 3Y-11.47%
Revenue growth 5Y133.89%
Sales Q2Q%N/A
Revenue Next Year-90.97%
Revenue Next 2Y-75.39%
Revenue Next 3Y-52.73%
Revenue Next 5Y37.92%
EBIT growth 1Y-19.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y56.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.97%
OCF growth 3YN/A
OCF growth 5YN/A

LIPOCINE INC / LPCN FAQ

What is the ChartMill fundamental rating of LIPOCINE INC (LPCN) stock?

ChartMill assigns a fundamental rating of 4 / 10 to LPCN.


What is the valuation status of LIPOCINE INC (LPCN) stock?

ChartMill assigns a valuation rating of 2 / 10 to LIPOCINE INC (LPCN). This can be considered as Overvalued.


What is the profitability of LPCN stock?

LIPOCINE INC (LPCN) has a profitability rating of 1 / 10.


How financially healthy is LIPOCINE INC?

The financial health rating of LIPOCINE INC (LPCN) is 7 / 10.